Parathyroid hormone therapy for osteoporosis-Reference-Cited by-同舟云学术

Parathyroid hormone therapy for osteoporosis

Published:2003-09 Issue:5 Volume:70 Page:315-317
ISSN:1297-319X
Container-title:Joint Bone Spine
language:en
Short-container-title:Joint Bone Spine

Author:

Audran Maurice,Insalaco Paolo

Publisher

Elsevier BV

Subject

Rheumatology

Reference26 articles.

1. Effects of risedronate on vertebral and non vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial;Harris;JAMA,1999

2. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures;Black;Lancet,1996

3. Comparison of new biochemical markers of bone turn over in late postmenopausal osteoporotic women in response to alendronate;Garnero;J Clin Endocrinol Metab,1994

4. Risedronate preserves bone architecture in osteoporotic postmenopausal women as measured by 3-D micro-computed tomography effects on bone turnover;Borah;J Bone Miner Res,2002

5. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women;Boivin;Bone,2000

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A bicistronic expression strategy for large scale expression and purification of full-length recombinant human parathyroid hormone for osteoporosis therapy;Protein Expression and Purification;2010-02

2. Activities of the deriviatives of chitin on the osbeoblast proliferation and the effect on bone strength in ovariectomized rats;Wuhan University Journal of Natural Sciences;2006-05

3. Strontium: a new treatment for osteoporosis;Joint Bone Spine;2004-07

4. Le strontium : un nouveau traitement de l'ostéoporose;Revue du Rhumatisme;2004-07